Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Most loved Web-based feature: Which Stage Do You Like - 2Vote In favor of Your Favored Occasion Arranging Administration
- 3Peloton recalls more than 800,000 bikes after broken seat posts injure users
- 4Vote in favor of Your #1 Climbing boots Now
- 5James Webb Space Telescope watches 'Jekyll and Hyde' galaxy shapeshift into a cosmic monster
- How to watch the ‘Wicked: One Wonderful Night’ special — now streaming
- Bayer reports positive results for blood thinner after 2023 setback
- Shredded cheese sold in dozens of states recalled due to potential for metal fragment contamination
- Venezuelans in Madrid celebrate Maduro's capture
- Are protests pushing Iran's Islamic regime toward a tipping point?
- Norovirus is spreading earlier again this year, wastewater data shows
- Untamed life Safe-havens All over the Planet Offering Remarkable Creature Experiences
- Massachusetts court hears arguments in lawsuit alleging Meta designed apps to be addictive to kids
- Everyone knows F1 is for the girls. I wandered into the Las Vegas desert to find out why.
